Treatment of fibromyalgia

Kwiatek, Richard

doi:10.18773/austprescr.2017.056

Cited by 35 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the etiopathogenesis of FMS could not be fully established, hormonal disorders, dysfunction of nervous system, immune problems, micro-circulation disorders in muscles and genetic predisposition may be involved in FMS. In some studies, FMS prevalence was reported to be 2 to 7% in general population with female preponderance 18 . In a study on MS patients and healthy volunteers, Marrie et al found that FMS frequency was 3.5 folds higher in MS patients when compared to the general population 19 .…”

Section: Discussionmentioning

confidence: 99%

Effects of Comorbid Fibromyalgia Syndrome on activities of daily living in multiple sclerosis patients

Ulusoy

2020

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Objective: To investigate the frequency of Comorbid Fibromyalgia Syndrome and its effects on quality of life and activities of daily living without any known psychiatric problem (schizophrenia or bipolar disorder) or severe disability, other than depression, in patients with multiple sclerosis, which is known to be a chronic disease in young adults. Methods: The study included 103 patients diagnosed with multiple sclerosis, following McDonald criteria, who had relapsing remitting disease. The Fibromyalgia Impact Questionnaire, Beck Anxiety Inventory, Beck Depression Inventory, Pittsburgh Sleep Quality Index, Fatigue Severity Scale, and Multiple Sclerosis Quality of Life-54 were applied for all patients. Results were analyzed using statistical methods. Results: Mean age was 35.04±8.72 years in the study population. The Expanded Disability Status Scale (EDSS) score was 2.21±0.93. Comorbid Fibromyalgia Syndrome was detected in 20 patients (19.4%). The mean score of Multiple Sclerosis Quality of Life-54 was found to be significantly higher in multiple sclerosis patients with Comorbid Fibromyalgia Syndrome when compared to those without it (34.80±9.14 versus 71.67±13.95; p<0.05). Conclusion: These results indicate that increased frequency of Comorbid Fibromyalgia Syndrome in multiple sclerosis causes worsening in activities of daily living and quality of life, delayed diagnosis, disability progression, and increased admission rates. Questioning and appropriately managing Comorbid Fibromyalgia Syndrome in clinical practice are important to improve the quality of life in multiple sclerosis patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Comorbid Fibromyalgia Syndrome on activities of daily living in multiple sclerosis patients

Ulusoy

2020

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…This chronic stress model was established by repeating exposure to cold stress for 5 days and reported to be useful as a IBS and fibromyalgia models . Similar to IBS, fibromyalgia is also thought to be associated with stress and often coexists and overlaps with IBS . We previously demonstrated SART stress rats showed marked visceral hypersensitivity to CRD, and this visceral hypersensitivity sustained for over 2 weeks even after the cessation of the SART stress .…”

Section: Discussionmentioning

confidence: 99%

Pharmacological evaluation of a novel corticotropin‐releasing factor 1 receptor antagonist T‐3047928 in stress‐induced animal models in a comparison with alosetron

Itomi

Tanaka

Matsushita

et al. 2020

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background:The major symptoms of irritable bowel syndrome (IBS) are changes in bowel habits and abdominal pain. Psychological stress is the major pathophysiological components of IBS. Corticotropin-releasing factor (CRF) is a well-known integrator in response to psychological stress. In this study, a novel CRF1 receptor antagonist T-3047928 was evaluated in stress-induced IBS models of rats to explore its potency for IBS. Methods: Plasma adrenocorticotropic hormone (ACTH) levels after intravenous oCRH challenge were measured as a pharmacodynamic marker. Efficacies of oral T-3047928 were compared with oral alosetron, a 5-HT3 antagonist, on conditioning fear stress (CFS)-induced defecation, restraint stress (RS)-induced acute visceral pain, specific alteration of rhythm in temperature (SART) stress-induced chronic visceral pain, and normal defecation. Results: T-3047928 (1-10 mg/kg, p.o.) demonstrated a dose-dependent inhibition on oCRH-induced ACTH secretion. In disease models, T-3047928 suppressed fecal pellet output induced by CFS and improved both acute and chronic visceral hypersensitivity induced by RS and SART stress, respectively. Alosetron was also efficacious in stress-induced defecation and visceral pain models at 1 and 10 mg/kg, respectively.Alosetron, however, also suppressed normal defecation at lower those. On the other hand, T-3047928 did not change normal defecation even at higher dose than those in disease models. Conclusion:T-3047928 is an orally active CRF1 antagonist that demonstrated potent inhibitory effects in stress-associated IBS models with no effect on normal defecation. Therefore, it is suggested that T-3047928 may have a potency as a novel option for IBS-D therapy with minimal constipation risk. K E Y W O R D SAlosetron, CRF1 receptor antagonist, defecation, irritable bowel syndrome (IBS), stress, T-3047928, visceral pain

show abstract

“…Moreover, drugs should be started at low doses and cautiously increased because some patients, either do not tolerate or benefit from drug therapy. Because sleep disturbance, pain and psychological distress are the most amenable to drug therapy, drugs should be chosen to manage the individual’s predominant symptoms [ 35 ]. Currently, several drugs are frequently used alone or in combination to manage FM symptoms; however, the US FDA indicated for FM only three: two selective serotonin and norepinephrine reuptake inhibitors (SNRIs), duloxetine and milnacipran, and an anticonvulsant, pregabalin [ 36 ].…”

Section: Therapymentioning

confidence: 99%

Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies

Maffei

2020

IJMS

View full text Add to dashboard Cite

Fibromyalgia (FM) is a syndrome that does not present a well-defined underlying organic disease. FM is a condition which has been associated with diseases such as infections, diabetes, psychiatric or neurological disorders, rheumatic pathologies, and is a disorder that rather than diagnosis of exclusion requires positive diagnosis. A multidimensional approach is required for the management of FM, including pain management, pharmacological therapies, behavioral therapy, patient education, and exercise. The purpose of this review is to summarize the recent advances in classification criteria and diagnostic criteria for FM as well as to explore pharmacotherapy and the use of alternative therapies including the use of plant bioactive molecules.

show abstract

Treatment of fibromyalgia

Cited by 35 publications

References 38 publications

Effects of Comorbid Fibromyalgia Syndrome on activities of daily living in multiple sclerosis patients

Effects of Comorbid Fibromyalgia Syndrome on activities of daily living in multiple sclerosis patients

Pharmacological evaluation of a novel corticotropin‐releasing factor 1 receptor antagonist T‐3047928 in stress‐induced animal models in a comparison with alosetron

Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies

Contact Info

Product

Resources

About